GAITHERSBURG, Md. & SHIN-YOKOHAMA, Japan — MEDINET Co. Ltd. (TSE: #2370) and MaxCyte, Inc. announce the publication of the results of their scientific collaboration demonstrating that the use of MaxCyte’s cell loading technology results in 5 – 20 fold enhancement in potency of dendritic cell vaccines. The manuscript entitled ‘Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL’ was published in the journal International Immunopharmacology and can be accessed online athttps://dx.doi.org/10.1016/j.intimp.2013.01.009.

“This publication provides clear scientific evidence of MEDINET’s leadership position in bringing advanced immunotherapies to cancer patients in Japan,” says Mr. Yoshiji Kimura, MEDINET’s Chief Executive Officer, “and will enhance our ability to provide the highest quality cancer immuno-cell therapies through our expanding network of Contracted Medical Institutions.”

“MEDINET is the leader of the world in cell-based therapies, with world-class expertise in immunotherapeutics,” says Douglas A. Doerfler, President and Chief Executive Officer of MaxCyte, “and we look forward to continuing to build on our strong and long-standing partnership.”

MEDINET has previously entered into an exclusive license agreement to use MaxCyte’s proprietary cell loading system to support clinical studies and commercialize treatment of cancer patients; and subsequently expanded the license to additional Asia-Pacific countries. MEDINET is currently marketing its cancer immunotherapy service in Japan and the largest provider in the country.

About MEDINET

MEDINET is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, MEDINET provides medical institutions with advanced technologies and knowhow in: cell processing and culturing, quality control, and facility management with respect to the immuno-cell therapy. MEDINET has extensive experience in autologous cell processing; with nearly 15,000 cancer patients treated in actual clinical practice through more than 124,000 cell therapy manufacturing processes. MEDINET continues to invest in R&D to improve cell processing technologies in an effort to increase efficacy in collaborative clinical studies with university hospitals and medical institutions. MEDINET went public in October, 2003 on the MOTHERS, Tokyo Stock Exchange.

For more information, visit https://www.medinet-inc.co.jp/english/.

About MaxCyte

MaxCyte is the leading provider of clinical and commercial high throughput cell modification technologies to global leaders in life sciences industry. MaxCyte’s transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases. By providing unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods. MaxCyte markets the MaxCyte® STX™ Scalable Transfection System to biopharmaceutical companies for cell-based drug screening and small molecule drug discovery.